Startup

Cellestia Biotech SA

Description

Cellestia Biotech SA is a Swiss biopharmaceutical company focused on pioneering innovative therapeutics for autoimmune diseases and multi-drug resistant cancers. Their lead compound, CB-103, targets the CSL-NOTCH transcription complex, addressing unmet medical needs by developing first-in-class therapies. With a strong emphasis on patient dedication, Cellestia aims to extend and improve the quality of life for patients with limited treatment options. By overcoming dose-limiting toxicities associated with NOTCH inhibitors, Cellestia's approach holds promise in the oncology and autoimmune markets. With an Investigational New Drug (IND) approval in place, CB-103 is set to enter Proof-of-Concept clinical studies for graft-versus-host disease (GvHD), with successful Phase 2 trials demonstrating efficacy in treating patients with multi-drug resistant cancers. Additionally, Cellestia is advancing a range of pre-clinical candidates for chronic autoimmune indications, positioning itself to bring innovative therapies to patients across various medical needs.

About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.